跳至主要内容
临床试验/NCT04159337
NCT04159337Unknown不适用

A Prospective Study on Companion Diagnosis by NGS-based Large-panel in Targeted Drug Delivery and Immunotherapy of Lung Cancer

Shanghai Chest Hospital1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2019年8月30日最近更新:
适应症

试验速览

阶段
不适用
入组人数
2,000
试验地点
1
主要终点
Progression-free survival (PFS)

研究概览

简要总结

Companion diagnosis by large-panel is in increasing acceptance and need during clinical cancer management. The purpose of this trial is to investigate the benefit of large-panel NGS analysis in companion diagnosis of advanced lung cancer patients and further optimize the parameters.

详细描述

Fresh tumor tissues and matched blood cells will be analyzed by large-panel (Berryoncology, lnc.) for multiple molecular biomarkers including mutations with sensitivity/resistance to targeted therapies, tumor mutational burden (TMB), microsatellite instability (MSI) status, etc., Therapeutic approach and outcome will be followed-up to inspect the clinical benefit by large-panel analysis. In addition, selected samples will be analyzed by WES to assess the correctness of TMB estimated by large-panel.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant aged 18 or above, and gender unrestricted
  • Individual with pathologically diagnosed lung cancer

排除标准

  • Patients with concomitant other tumors
  • Individual with severe cardiopulmonary insufficiency and hypoproteinemia
  • Women who were pregnant and were during their lactation

结局指标

主要结局

Progression-free survival (PFS)

时间窗: through the whole study period, an average of 3 year

PFS refers to the time from initial treatment to the time of disease progression or death

Tumor Mutational Burden (TMB)

时间窗: halfway of the study, an average of 1.5 year

TMB is defined as the total number of detected somatic mutation counts in coding regions per million bases

次要结局

  • Other biomarkers(halfway of the study, an average of 1.5 year)
  • Overall survival (OS)(through the whole study period, an average of 3 year)
  • Clonality(halfway of the study, an average of 1.5 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lu Shun

Chief physician

Shanghai Chest Hospital

研究点 (1)

Loading locations...

相似试验

NGS-based Large-panel in Targeted Drug Delivery and... | 临床试验